Market stress hit US health insurers head-on after the Trump administration floated a 2027 Medicare Advantage payment update that upended earnings math across the sector. Investors moved fast. So did executives, actuaries, and strategy teams.
Equity markets elsewhere leaned upbeat, lifted by tech and a fresh S&P 500 record, yet managed care traded in its own ugly lane as tens of $bn in value vanished before lunch.
The trigger sits inside a proposal from the Centers for Medicare and Medicaid Services. CMS outlined an average Medicare Advantage payment lift of 0.09% for 2027.
Wall Street models, and most internal carrier forecasts, sat closer to 4-6%. The gap matters. Once medical inflation, utilisation, wages, and benefit creep enter the picture, executives aren’t reading the number as an increase.
Stocks priced it that way:
- UnitedHealth Group dropped about 18% to roughly $286.68.
- Humana slid more than 19% to near $213.
- CVS Health and Elevance Health together lost over $20 bn in market capitalisation.
Major insurers saw their stocks tumble sharply after the Trump administration proposed holding Medicare payments roughly flat in 2027. The small-than-expected increase comes amid concerns about rising health costs.
UnitedHealth Group released fourth-quarter earnings before Tuesday’s opening bell, with RBC analysts saying the earnings print and 2026 outlook were both “solid.” They chalked up the big slide in the shares to the latest insurance updates from the administration.
During the earnings call, UnitedHealthcare CEO Tim Noel called the CMS proposal “disappointing,” saying if finalized, “it will mean very meaningful benefit reductions.”
The damage stung more because Medicare Advantage has carried growth expectations for years, propped up by generous federal payments and favourable risk scoring. That formula looks shakier now.
For insurers, the issue runs deeper than a bad trading day. The proposed rates arrive with cost pressure already intense.
Senior medical trends keep running hot as deferred care returns, acuity rises, and high-ticket therapies spread. Labour and administrative costs stay elevated, especially in care management and clinical roles.
Oversight around risk adjustment and coding keeps tightening, shrinking room to offset weak headline rates through documentation.
UnitedHealth added fuel by pairing the policy jolt with softer 2026 revenue guidance and sizeable charges. Investors took it as confirmation that Medicare margins were thinning even before 2027 enters the frame.
Humana felt the blow harder still. As one of the cleanest Medicare Advantage exposures in public markets, its valuation rests heavily on reimbursement assumptions now under fire.
If CMS finalises the proposal close to current form, carriers face an awkward 2027 bid season. One path protects margins by trimming benefits, lifting premiums, or narrowing networks, with enrolment losses the obvious risk.
The other defends membership and broker flow, holds benefits steady, and accepts weaker profitability while hoping capital markets stay patient. Neither feels comfortable amid louder political focus on Medicare spending and consumer affordability.
CMS framed the move as a push for payment accuracy and sustainability. Officials said the plan modernises risk adjustment and ties reimbursement more tightly to genuine clinical need, limiting excess outlays.
Administrator Mehmet Oz said the policies aim to make Medicare Advantage work better for beneficiaries. To insurers, the message sounds less soothing.
Washington doesn’t look eager to restore above-trend increases that carried margins in recent years. Pressure on coding intensity and supplemental benefits looks set to continue.
More than half of Medicare beneficiaries now sit in Medicare Advantage, drawn by low or zero-dollar premiums and extras absent from traditional Medicare. Scale changed the politics.
As enrolment expanded, so did scrutiny over perceived overpayments and loose guardrails. According to Beinsure, the programme’s popularity now cuts both ways, anchoring carrier revenue while pulling it deeper into budget fights.
The selloff also exposed a split inside insurance. Health names absorbed the shock. Others barely flinched. American International Group and The Hartford dipped less than 1%.
- Life insurers such as MetLife and Prudential Financial traded up around 1-2%.
- In P&C, Progressive edged higher, Allstate slipped more, yet nothing close to managed care’s collapse.
According to our data, this wasn’t a verdict on insurance writ large. It was a Medicare-specific reckoning.
Capital rotation inside the sector looks likely as investors lean toward lines with clearer regulation and shorter-tail risk. For health plans, time pressure builds.
If the 0.09% figure survives into April with limited tweaks, teams have months, not years, to recalibrate.
Questions pile up quickly. How far benefit richness drops before Star Ratings, retention, and broker support crack. Whether networks and utilisation controls still tighten without provoking backlash or regulators.
Whether buybacks, dividends, or dealmaking slow if Medicare earnings reset lower. And whether diversification away from Medicare Advantage accelerates into commercial, Medicaid, specialty benefits, or services.
CMS also signalled clampdowns on billing practices it views as aggressive. Plans reliant on documentation gains may enter 2027 with thinner margins than rate tables alone suggest. The starting line shifts.
The Centers for Medicare & Medicaid Services proposed a net average year-over-year payment increase of 0.09% in 2027 for Medicare Advantage members. In comparison, Medicare Advantage payments in 2026 rose 5.06% from 2025.
The proposed payment increase was well below Wall Street’s expectations, with RBC Capital Markets analysts expecting an “at least a mid-single digit increase.” The analysts noted that historically, the final payment rate is higher than the initial proposal.
Dr. Mehmet Oz, CMS administrator, said the “proposed payment policies are about making sure Medicare Advantage works better for the people it serves,” while “protecting taxpayers from unnecessary spending that is not oriented towards addressing real health needs.”
The CMS proposal also includes updates to the Medicare Advantage risk adjustment model, such as excluding diagnosis information not associated with a specific beneficiary encounter.
For now, the update remains a proposal. CMS typically locks Medicare Advantage rates in early April after heavy lobbying. Carriers will argue tight payments shrink benefits, strain access, and weaken a programme central to Medicare delivery.
Between now and then, watch for revised guidance from major insurers, widening valuation gaps between diversified groups and Medicare-heavy plays, and hints from lawmakers on whether the final rule softens or stays austere.
The episode lands as a blunt reminder. In Medicare Advantage, policy risk outruns underwriting risk when sentiment turns.
Executives now translate a tiny 0.09% headline number into page-by-page resets of products, capital, and strategy. Investors decide who adapts fast enough, and who priced for rules that no longer apply.
